IDXX

IDEXX LABORATORIES INC

Apr 05 • 04:00PM ET

518.10

+6.11 (+1.19%)

Company Profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to ... read more

Full Time Employees 11,000

Phone 207 556 0300

Website https://www.idexx.com

CEO Mr. Jonathan J. Mazelsky

IPO Date 1991-06-21

Sector Healthcare

Industry Medical - Diagnostics & Research

Address One IDEXX Drive, Westbrook, ME 04092

Balance Sheet

Total Cash $163,970,000

Total Debt $1,037,232,000

Current Ratio 1.16

Quick Ratio 0.61

Profitability

Gross Margin 61.28%

Net Margin 22.76%

ROE 61.81%

ROA 27.85%

ROIC 36.70%

Balance Sheet

Total Cash $163,970,000

Total Debt $1,037,232,000

Current Ratio 1.16

Quick Ratio 0.61

Profitability

Gross Margin 61.28%

Net Margin 22.76%

ROE 61.81%

ROA 27.85%

ROIC 36.70%

Name	IDEXX LABORATORIES INC	Sector	Healthcare	Currency	USD	Relative Volume	2.2	Market Cap	32021
Current Ratio	1.31	Dividend / Share	0.0	EPS	10.67	Revenue	3897504000	P/S	8.2
P/E	36.1	Beta	0.83	Income	887867000	Volume	1635274	Average Volume	741951
Distance to 200DMA	-13.29%	200 DMA	454.07	50 DMA	435.37	ROA	26.5	ROE	55.8
Distance to 50DMA	-9.56%	Return 1Y	-24.87%	Return YTD	-4.77%	Forward PE		Qtly Growth YOY
Debt/Eq	1.06	P/B	20.1	Dividend Yield	0.0%	Net Margin	22.78%	Payout Ratio	0.0

Performance

52 Week Range 0.0%

Distance to 200DMA 0.0%

Day Change Percent $0.00

Performance Range

Day

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Balance Sheet

Total Cash $308,636,000

Total Debt $977,318,000

Current Ratio 1.42%

Quick Ratio 0.81%

Profitability

Valuation

Price to Earnings 47.08

Price to Book 29.10

Price to Sales 10.72

Price to Free Cash Flow 50.29

Dividends

Payout Ratio 0.00%

Dividend Yield 0.00%

Dividend Amount $0.00

Performance

52 Week Range 0.0%

Distance to 200DMA 0.0%

Day Change Percent $0.00

Company Profile

Full Time Employees 11,000

Phone 207 556 0300

Website https://www.idexx.com

CEO Mr. Jonathan J. Mazelsky

IPO Date 1991-06-21

Sector Healthcare

Address One IDEXX Drive, Westbrook, ME 04092

Histogram - Daily

Balance Sheet

Total Cash $308,636,000

Total Debt $977,318,000

Current Ratio 1.42%

Quick Ratio 0.81%

Profitability

Gross Margin 0.6070%

Net Margin 0.2250%

ROE 0.55%

ROA 0.26%

Company Profile

Full Time Employees 11,000

Phone 207 556 0300

Website https://www.idexx.com

CEO Mr. Jonathan J. Mazelsky

IPO Date 1991-06-21

Sector Healthcare

Address One IDEXX Drive, Westbrook, ME 04092

Monthly Win Rate

Balance Sheet (Multi-Column Example)

	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Cash & Short Term Investments	53,775.0	65,171.0	61,801.0	67,150.0	73,100.0	61,555.0	62,482.0	55,872.0
Receivables	59,306.0	66,243.0	43,172.0	41,150.0	50,102.0	60,985.0	39,186.0	35,899.0
Inventory	6,911.0	7,286.0	6,165.0	6,232.0	6,511.0	6,331.0	7,351.0	7,482.0

Latest News

5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil

Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.

2025-05-15 09:11:13 - zacks.com

IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits

IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normali

2025-05-14 14:35:10 - seekingalpha.com

Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?

Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year.

2025-05-14 10:41:31 - zacks.com

IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor D

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financ

2025-05-13 14:30:00 - businesswire.com

Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street es

2025-05-01 10:36:17 - zacks.com

IDEXX Laboratories, Inc. (IDXX) Q1 2025 Earnings Conference Call Transcript

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Emerson - EVP, CFO and Treasurer Jay Mazelsky - President and CEO Conference

2025-05-01 10:35:25 - seekingalpha.com

Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.96 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.81 per share a year ago.

2025-05-01 08:40:23 - zacks.com

IDEXX Laboratories raises annual profit view on strong demand for its pet diagno

Animal diagnostics maker IDEXX Laboratories on Thursday raised its annual profit forecast after it beat Wall Street estimates for quarterly profit, as it benefited from customer retention and increase

2025-05-01 08:21:46 - reuters.com

IDEXX Laboratories Announces First Quarter Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. “IDEXX drove solid execution in the fir

2025-05-01 06:30:00 - businesswire.com

Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?

The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.

2025-04-30 10:35:40 - zacks.com

Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2025-04-29 10:50:57 - zacks.com

Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections f

Besides Wall Street's top -and-bottom-line estimates for Idexx (IDXX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quar

2025-04-29 10:21:11 - zacks.com

Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2025-04-24 11:08:53 - zacks.com

IDXX Gears Up for Q1 Earnings: What to Expect From the Stock?

IDEXX Laboratories' first-quarter 2025 performance is expected to have benefited from a strong execution against strategic priorities.

2025-04-21 09:35:41 - zacks.com

IDEXX (IDXX) Surges 10.0%: Is This an Indication of Further Gains?

IDEXX (IDXX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the

2025-04-10 06:50:37 - zacks.com

Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

2025-04-09 10:45:33 - zacks.com